COMP <GO>
HBIO vs ABBV // GROSS PROFIT MARGIN
Harvard Bioscience Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HBIO 2
— ABBV 9
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $8.80 (+4.51%) • MKT CAP: $40.1M
gross-margins
57.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HBIO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HBIO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 57.70% | 70.20% | -12.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.66% | 3.47% | +10.19 | HBIO | /fcf-yield <GO> |
| Operating Margin | -56.10% | 24.60% | -80.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -8.10% | 8.60% | -16.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.8 | 65.1 | +3.68 | HBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.1M | $513.86B | -$513.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HBIO REV | ABBV REV | HBIO GROSS % | ABBV GROSS % | HBIO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $86.5M | $61.16B | 57.7% | 70.2% | $5.5M | $17.82B |
| FY 2024 | $94.1M | $56.33B | 58.2% | 70.0% | -$1.2M | $17.83B |
| FY 2023 | $112.3M | $54.32B | — | — | $14.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HBIO // BETA —
ABBV // BETA 1.15